Directed share issue in XVIVO Perfusion AB (SE) — SEK 440 million

Carnegie acted as joint bookrunner in the directed share issue of 1,600,000 new shares at a subscription price of SEK 275 per share. XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. XVIVO’s solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.